Caroline Palomeque
Stock Analyst at Maxim Group
(2.03)
# 3,621
Out of 5,182 analysts
10
Total ratings
55.56%
Success rate
4.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.27 | +252.42% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $31.97 | +84.55% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $275.94 | -44.19% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $68.40 | -15.20% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $231.05 | -28.15% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $20.25 | +92.59% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.34 | +553.10% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $3.61 | +1,008.03% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.27
Upside: +252.42%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $31.97
Upside: +84.55%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $275.94
Upside: -44.19%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $68.40
Upside: -15.20%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $231.05
Upside: -28.15%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $20.25
Upside: +92.59%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.34
Upside: +553.10%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $3.61
Upside: +1,008.03%